Sheba researcher: Antiparasitic drug reduces length of COVID-19 infection
According to his yet to be published data, Schwartz said that the drug was shown to help “cure” people of the virus within just six days.
Science & Tech
An Israeli tropical-disease expert says he has new proof that a drug used to fight parasites in third-world countries could help reduce the length of infection for people who contract coronavirus.
Prof. Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba Medical Center in Tel Hashomer, last week completed a clinical trial of the US Food and Drug Administration-approved drug ivermectin, a broad-spectrum antiparasitic agent that has also been shown to fight viruses.
The double-blind, placebo-controlled study included 100 people with mild to moderate cases of the disease who were not hospitalized for the virus. It tested whether ivermectin could shorten the viral shedding period, allowing them to test negative for coronavirus and leave isolation in only a few days.
According to his still unpublished data, Schwartz said the drug was shown to help “cure” people of the virus within just six days. Moreover, the chances of testing negative for coronavirus were three times higher for the group who received ivermectin than the placebo, he told The Jerusalem Post.
“From a public-health point of view, the majority of patients with corona are mild cases, and 90% of these people are isolated outside of the hospital,” Schwartz said. “If you have any kind of drug that can shorten the duration of the infectiousness of these patients, that would be dramatic, as then they will not infect others.”
Moreover, instead of isolating for a minimum of 10 days and maybe more, this period could be shortened, benefiting the economy.
Finally, although Schwartz’s study did not focus on this, he said the results indicate that it is likely if the drug were given at the beginning of one’s illness, it could prevent deterioration and hospitalization.